1. Home
  2. MYGN vs PRTH Comparison

MYGN vs PRTH Comparison

Compare MYGN & PRTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • PRTH
  • Stock Information
  • Founded
  • MYGN 1991
  • PRTH 2005
  • Country
  • MYGN United States
  • PRTH United States
  • Employees
  • MYGN N/A
  • PRTH N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • PRTH EDP Services
  • Sector
  • MYGN Health Care
  • PRTH Technology
  • Exchange
  • MYGN Nasdaq
  • PRTH Nasdaq
  • Market Cap
  • MYGN 642.0M
  • PRTH 545.8M
  • IPO Year
  • MYGN 1995
  • PRTH N/A
  • Fundamental
  • Price
  • MYGN $7.96
  • PRTH $7.29
  • Analyst Decision
  • MYGN Hold
  • PRTH Strong Buy
  • Analyst Count
  • MYGN 13
  • PRTH 4
  • Target Price
  • MYGN $13.50
  • PRTH $12.25
  • AVG Volume (30 Days)
  • MYGN 1.5M
  • PRTH 413.1K
  • Earning Date
  • MYGN 11-06-2025
  • PRTH 11-06-2025
  • Dividend Yield
  • MYGN N/A
  • PRTH N/A
  • EPS Growth
  • MYGN N/A
  • PRTH N/A
  • EPS
  • MYGN N/A
  • PRTH 0.26
  • Revenue
  • MYGN $832,900,000.00
  • PRTH $918,558,000.00
  • Revenue This Year
  • MYGN $0.17
  • PRTH $13.01
  • Revenue Next Year
  • MYGN $6.19
  • PRTH $10.85
  • P/E Ratio
  • MYGN N/A
  • PRTH $27.49
  • Revenue Growth
  • MYGN 3.83
  • PRTH 12.86
  • 52 Week Low
  • MYGN $3.76
  • PRTH $5.01
  • 52 Week High
  • MYGN $26.60
  • PRTH $12.47
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 57.10
  • PRTH 50.55
  • Support Level
  • MYGN $7.04
  • PRTH $6.68
  • Resistance Level
  • MYGN $8.25
  • PRTH $7.42
  • Average True Range (ATR)
  • MYGN 0.38
  • PRTH 0.23
  • MACD
  • MYGN -0.06
  • PRTH 0.02
  • Stochastic Oscillator
  • MYGN 54.77
  • PRTH 72.22

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

About PRTH Priority Technology Holdings Inc.

Priority Technology Holdings Inc is a provider of merchant acquiring and commercial payment solutions to small and medium business enterprises in the United States. The company has three reportable segments which are SMB Payments, B2B Payments, and Enterprise Payments. SMB Payments segment which generates the majority of revenue provides full-service acquiring and payment-enabled solutions for B2C transactions, leveraging Priority's proprietary software platform, distributed through ISO; the B2B Payments segment provides AP automation solutions to corporations, software partners, & industry FIs: and Enterprise Payments segment provides embedded payment & treasury solutions to enterprise customers to modernize legacy platforms & accelerate software partners' strategies to monetize payments.

Share on Social Networks: